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To isolate new types of vesicular stomatitis virus (VSV) mutants, a four-stage
screen was developed which identifies and characterizes mutants capable of
complementing the defect in the VSV temperature-sensitive mutant tsGll. Two
types of mutants of VSV, Indiana serotype, have been found by using the screen;
they are new temperature-sensitive mutants which are, of necessity, not in
complementation group I and mutants which do not produce plaques under
conditions of single infection at 31 C (the normal permissive temperature) and
are, therefore, called complementation-dependent mutants. The newly isolated,
temperature-sensitive mutants fall into three complementation groups, two of
which are congruent with known complementation groups; the newly identified
group extends to six the number of complementation groups ofVSV Indiana. The
nature of the complementation-dependent mutants has not been established, but
one was shown to not contain a significant deletion in its nucleic acid.
Temperature-sensitive mutants of vesicular
stomatitis virus (VSV), as well as host-range
mutants, have been isolated in a number of
laboratories (4, 6-9, 11, 13, 16). Of the fiye
complementation groups of mutants in the
Indiana serotype, complementation group I con-
tains most of the mutants which have been
isolated; it presumably corresponds to the vi-
rion-associated transcriptase which is the L
(large) protein (2, 5, 12, 18). Group V appears to
represent the envelope-associated G protein
(21). Groups II, III, and IV have less certain
associations. Mutants of the New Jersey sero-
type of VSV fall into six complementation
groups (14).
To increase the catalog of VSV mutants, we
initiated a program of isolation of conditional
lethal mutants which would not necessarily
depend on high temperature as the nonpermis-
sive condition. A way was especially sought
which would allow the isolation of possible
amber mutants and complementing deletions
(as opposed to defective, interfering particles
which do not appear to complement; 15). As the
procedure developed, it also automatically
eliminated group I ts mutants and therefore
generated new mutants in the other groups.
The conditional system involved identifica-
tion of mutants able to grow by complementa-
lPresent address: The Rockefeller University, New York,
N.Y. 10021.
"Present address: Boston City Hospital, Boston, Mass
02118.
41
tion with a known ts mutant at high tempera-
ture but unable to grow by themselves at high
temperature. The mutants were screened by
infecting cells at a high multiplicity of infection
(MOI) with the ts mutant, co-infecting with
mutagenized VSV at a low MOI, and plating
the infected cells for infective centers at high
temperature on a monolayer of uninfected cells.
All mutants isolated this way can be called
complementation dependent, but we have re-
served the notation cd for mutants which ap-
peared to be complementation-dependent but
not temperation sensitive.
The details of the screen and some mutants
which have been selected with it are described
here. We caution investigators who wish to use
the methods that the procedures work well as
described, but that even small variations in
parameters such as temperature or MOI can
lead to problems.
MATERIALS AND METHODS
Cells and media. Mouse L cells were grown in
-ontinuous suspension culture at 5 x 10, to 1 x 106
cells/ml in Joklik-modified minimal essential me-
dium (GIBCO) with added 7% fetal bovine serum.
Monolayer cultures were prepared by seeding 5 x 106
L cells per 5-cm plastic tissue culture plate 1 to
several hours before use. These cultures were main-
tained in medium supplemented with 1.8 mM CaCl,,
and incubations were conducted at the indicated
temperatures in a humidified atmosphere of 5% CO,.
Purified virus stocks, free of interfering DI-T parti-
cles, were prepared on Chinese hamster ovary cells as
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described previously (17).
Viruses. The wild-type strain of VSV used in these
experiments was the large-plaque variant of the
Indiana serotype isolated and described by Wagner et
al. (19). Plaque assays were carried out as previously
described (19), with appropriate medium and serum
for L-cell monolayers. All VSV temperature-sensitive
(ts) mutants of the G (Glasgow) series and tsO45 (from
the Orsay collection) were kindly supplied by C. R.
Pringle.
Preparation of mutagenized virus stocks. Puri-
fied wild-type stocks of VSV were treated as described
with one of the following mutagens.
(i) 5-Fluorouracil. A suspension culture of 5 x 107
L cells in 10 ml of medium with 1.8 mM CaCl, was
infected with wild-type VSV at an input MOI of 0.5.
After an adsorption period of 30 min at 31 C, the
samples were centrifuged to remove unadsorbed virus
and suspended in 10 ml of medium plus 4% serum
containing 0.3 to 1.0 mg of 5-fluorouracil per ml. The
infected cells were incubated in suspension for 8 h at
31 C, after which time the supernatants were col-
lected, dialyzed against the medium, and stored at
-70 C. Virus yields were 1.5 x 10-1 to 1.3 x 10-' of
those obtained in the absence of mutagen.
(ii) N-methyl-N'-nitro-N-nitrosoguanidine. Pu-
rified stock suspensions of VSV were incubated at
room temperature for 15 min in 1.0 mg of nitrosoguani-
dine per ml by the method of Burge and Pfefferkorn
(1). After dialysis against fresh medium, the samples
were stored at -70 C. Survival of the virus was 2 x
10-4.
(iii) Nitrous acid. By the procedure of Granoff
(10), VSV stocks were incubated at room temperature
with 1 M NaNO2 in 0.25 M sodium acetate buffer (pH
4.8). At 1-min intervals, samples were removed, and
the reactions were terminated by 1:100 dilutions into
phosphate-buffered saline.
Complementation by infective center assay.
Complementation between tsGll and other ts mu-
tants in individual, mixedly infected cells was assayed
by plating infected cells on confluent L-cell mono-
layers under plaque assay conditions and then
incubating the plates at the nonpermissive tempera-
ture. Suspension culture L cells were concentrated to
5 x 106 cells/ml and infected at a multiplicity of 5
PFU/cell with tsGll (the helper) and 0.1 PFU/cell
with the mutant to be tested (called tsX below). Cells
infected with tsX alone also received 0.1 PFU/cell.
After a 45-min adsorption period at the permissive
temperature (31 C), the infected cells were washed
twice with medium by centrifugation to remove
unadsorbed virus and finally resuspended in the
original volume with fresh medium. Recovery of
infected cells after the centrifugation steps was ap-
proximately 50 to 60% by direct count. Appropriate
dilutions were made, and 0.2-ml samples of cells were
plated on confluent monolayers of uninfected L cells.
Forty minutes at 31 C was allowed for attachment of
the infected cells, and then an overlay consisting of
0.9% agar in medium containing 1.8 mM CaCl2,
nonessential amino acids, and 2.0% fetal calf serum
was added. The plates were incubated for 2 days at
either 31 C or 38.5 C, as appropriate, and the appear-
ance of plaques at 38.5 C on the monolayers seeded
with mixedly infected cells was interpreted as evi-
dence for complementation in single infective centers.
The results are expressed as the complementation
efficiency coefficient:
Complementation efficiency coefficient for tsX
Ft8G11 plus tsXl
_tX3.CttrL 38.5 C titer j [tsX38.5 C titer]
[tsX 31 C titer] - [tsX 38.5 C titer]
The term subtracted from both numerator and de-
nominator corrects for the presence of tsX revertants,
generally a negligible number. L cells infected with
tsG1l at an MOI of 5 and plated as infective centers at
38.5 C demonstrated that the complementation re-
sults were not due to tsGl1 revertants or background
growth at the nonpermissive temperature.
Examination of virus in complementation
plaques (stage IV; Fig. 1). To examine the content
of complementation plaques, the agar over such
plaques was collected in a capillary tube, and the
virus was released into 1 ml of medium as described
(17). The virus was plated on L-cell monolayers which
were incubated for 2 days at 31 C, and well-isolated
plaques were then analyzed to determine if they
contained tsGll, a new ts mutant, or something else.
For the analysis, plates containing L cells sus-
pended in agar were used (3). For these, a 15-ml agar
base layer was prepared in plastic petri dishes (15 by
100 mm); it consisted of 0.9% agar, medium, 1.8 mM
CaCl,, nonessential amino acids, and 2% fetal calf
serum. Over this base layer was poured a suspension
of 107 L cells in the same agar medium which was
allowed to solidify. Some plates were also seeded with
4 x 106 L cells freshly infected with tsGll at an MOI
of 5 in the top layer in addition to the uninfected cells.
The plaques to be tested were stabbed with a sterile
toothpick, and the toothpick was then stabbed into
identical positions on three plates of L cells in agar
suspension, the last plate containing tsGll-infected
cells. After a number of plaques had been replicated
onto the three plates, one plate was incubated at 31 C,
one was incubated at 38.5 C, and the tsGll-contain-
ing plate was incubated at 38.5 C. After 2 days, the
plates were scored for growth, and the results for any
one tested plaque were recorded as (+) or (-) for each
of the three plates. These were incorporated into a
three-place code where growth at 31 C, 38.5 C, and
38.5 C plus helper were serially represented. A result
of (+ - -) was indicative of tsGll and a result of
(+ - +) indicated a new ts mutant. The (+ + +)
result is discussed below.
The new ts mutants were harvested from the 31 C
replica plates and cloned twice, and then purified
stocks free of defective, interfering particles were
prepared (17).
Complementation in high-MOI-infected mono-
layer cultures. The complementation groups of ts
mutants were determined by a modification of the
method of Cormack et al. (4). Monolayer cultures of
2.5 x 10' L cells were mixedly infected with pairs of ts
mutants, each at an input MOI of 5. However, an
MOI of 1 was used in these studies for tsG22 and
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Stage I
Mixedly infect L cells with tsG1l (MOI of 5) and VSV mutagen-
ized stock (MOI < 0.01). Plate infected cells on confluent,
uninfected monolayers. Incubate 2 days at 38.5 C. Pick isolated
plaques and elute in 1.0 ml of medium (*).
4
Stage II
Titer plaques at 31 C and 38.5 C. Retain only samples giving
low 38.5 C/31 C ratio.
Stage Ill
Conduct infective center Plate at 38.5 C with Retain only samples demon-
complementation assays added tsG1l (*) strating an enhanced infective
with and without added center formation with added
high MOI tsG11 helper Plate at 38.5 C without tsGll
added tsGll (*)
4
Stage IV
From any or all complementation plaques appearing in assays marked (*),
plate onto L-cell monolayers at 31 C and then replicate plaques with
toothpicks onto three plates of agar-L-cell suspensions.
xx x xxx xx x
xxxxx xxxxx xxxxx
xxxxx x\ xx XX xx
xx xx x
31C 38.5C 38.5C
(Seeded with tsGll-
infected cells)
FIG. 1. Screening procedure used to select potential complementation-dependent mutants. Asterisks (*)
indicate places in the screen where 38.5 C complementation plaques were picked and examined in stage IV of
the assay.
tsG41 because of the high background yields obtained
with these mutants. Controls for each member of a
tested pair of mutants were singly infected at twice
the MOI used in the mixed infection. Thirty minutes
was allowed for adsorption at 39 C (39 C was used for
this assay rather than 38.5 C because of the high
background yield at the lower temperature). The
monolayers were washed twice with 5.0 ml of medium
to remove unadsorbed virus and then covered with 5.0
ml of medium with 1.8 mM CaCl,, nonessential
amino acids, and 2.5% fetal bovine serum. The
medium was changed 90 min later to remove any virus
which may have eluted from the infected cells. The
supernatants were harvested 5.5 h after infection,
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centrifuged to remove any floating cells, and titered at
31 C. Results are expressed as a complementation
index, calculated as the ratio
Yield (tsA + tsB) during 39 C mixed infection
Yield tsA during 39 C single infection
where tsA and tsB are any pair of ts mutants and the
yield of tsA at 39 C exceeds that of tsB.
RESULTS
Complementation between ts mutants by
infective center assay. Previous studies of
complementation by VSV temperature-sensi-
tive mutants have involved mixed infections at
high multiplicities in mass cultures (4, 9).
Because our strategy for isolation of new mu-
tants involved infection of all members of a
population of cells by a helper mutant, infection
of some cells by a single particle of a new
mutant, and then determination of productive
infective centers as an assay for complementa-
tion, the feasibility of this methodology was
established by using known temperature-sensi-
tive VSV mutants.
Mutant tsGll acted as an efficient helper for
complementation in the infective center assay
with mutants from groups II, III, IV, and V.
Table 1 shows the relative plating efficiency of
the tested mutants at 38.5 C (nonpermissive
temperature) and 31 C (permissive tempera-
ture) along with a coefficient which measures
their ability to complement tsGll (calculated
as described in the Materials and Methods).
Mutant tsGll complements tsG22, tsG33,
tsG41, and tsO45 efficiently enough that almost
all of the particles able to form plaques at 31 C
can be detected by complementation in the
infective center assay. The data also confirm
TABLE 1. Properties of representative VSV ts
mutants in L cells
VSV Comple- Efficiency of tsG11 Comple-
mutant mentation plaque forma- efficnmutan
group tion at 38.5 Ca efficiency
tsG1l I < 10-6
tsG13 I 3 x 10-5 <1- 4
tsG114 I < 10-6 < 10-4
tsG22 II 5 x 10-6 0.92
tsG33 III 8 x 10-4 0.97
tsG41 IV 2 x 10-5 0.92
ts045 V 2 x 10-5 0.87
a Ratio of plaques formed at 38.5 C to those formed
at 31 C.
Calculated as described in Materials and
Methods.
that tsGll, tsG13, and tsG114 are all in the
same complementation group.
To determine if the complementation plaques
arising in the infective center assay contained
any recombinant progeny, the plaques were
assayed for wild-type virus. More than 99% of
the virus in these plaques was still temperature
sensitive. A few particles able to form plaques at
38.5 C were detected, but further replating of
these plaques did not yield stable recombi-
nants. We conclude that the complementation
plaques contain mainly the ts parent viruses
plus a few aggregated particles or heteropoly-
ploid particles in which the genomes of both
parents are enclosed in a single envelope. Such
particles have been previously implicated in
genetic studies with VSV ts mutants (20).
Mutants in group I are especially well-suited
as helpers in this complementation test because
at high MOI they give little or no background
growth in the infective center assay by them-
selves. Mutants from other groups were less
suitable as helpers; tsG22 gave too high a
background at 38.5 C; tsG41 gave only minute
complementation plaques at 38.5 C, and tsG22
gave a complementation efficiency coefficient of
0.1 to 0.5. We therefore used tsGll as the helper
virus in attempts to isolate complementation
dependent mutants.
Mutant screen. The procedure used to screen
for complementation-dependent mutants is
outlined in Fig. 1. In stage I, L cells were
infected at an MOI of 5 with tsGll and at an
MOI of 0.01 with mutagenized wild-type VSV.
These mixedly infected cells were then plated
onto confluent L cell monolayers and incubated
at 38.5 C (infective center assay described
above). Plaques which formed would be due
either to residual wild-type virus in the muta-
genized stock or to complementation between a
mutant and the tsGll helper.
To distinguish wild-type virus from new mu-
tants, isolated plaques from the infective center
assay were eluted into 1 ml of medium. In stage
II of the screen (Fig. 1), assays of 50 gliters of
the plaque eluates at 31 C and 38.5 C were
performed. Only samples exhibiting a very low
ratio of plaques at 38.5 C to those at 31 C were
retained. Such samples could have tsGll plus a
new ts mutant, tsGll plus a true cd mutant or
tsGll alone. With the three mutagens used,
about 5 to 10% of the stage I plaques were
considered suitable for further analysis.
Those plaques retained for further analysis
were then subjected to stage III of the screen to
select samples containing a mutant aside from
tsGll which would efficiently complement
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tsGll. For stage III, 0.1 ml of the original plaque
eluates from stage I were assayed for infective
center formation at 38.5 C with and without
added tsGll. Those samples showing at least an
eightfold enhancement of plaque formation at
38.5 C by tsGll were selected for further analy-
sis. About one-third of the 5-fluorouracil-
treated virus which passed stage II also passed
stage m (8 out of 26), 1 of 15 plaques from
nitrosoguanidine-treated virus passed stage III,
and 1 of 4 plaques from nitrous acid-treated
virus was retained.
Stage IV of the assay was designed to distin-
guish new ts mutants from cd mutants and to
allow isolation of the new ts mutants. Individ-
ual plaques arising at 38.5 C, from assays
marked in Fig. 1 with an asterisk, were picked
and plated at 31 C. Isolated plaques from these
plates were then picked with sterile toothpicks
and transferred to grid positions on three sepa-
rate plates each containing L-cell suspensions
in agar. One of these plates was also seeded with
tsGll-infected cells. The tsGll-containing
plate along with one of the other two were
incubated at 38.5 C; the third plate was incu-
bated at 31 C. The pattern of growth of virus
from one tested plaque was scored as (+) or (-)
on each of the three plates and recorded as a
three-place code.
All plaques submitted to stage IV analysis
had an excess of tsGll virus because they arose
due to complementation by tsGll. Therefore,
the most frequent result at stage IV was
(+ - -). In some of the plaques, a percentage
of the virus gave a (+ - +) result. These were
classed as non-group I, ts mutants because they
could grow by themselves at 31 C but not at
38.5 C, and they were able to grow at 38.5 C
when complemented by tsGll. For such mu-
tants, the plaques on the 31 C stage IV plate
were picked, the virus was recloned 2 or 3 times
at 31 C, and a stock was prepared. Further
analysis of such plaques is given below.
The proportion of new ts mutant virus in an
initial 38.5 C plaque was determined from the
ratio of plaques at 38.5 C with added tsGll to
plaques at 31 C and depended on the point on
the screen from which the plaque was obtained.
Stage I plaques, or stage III plaques with added
tsGll virus, generally contained at most 5 to
10% of the new ts mutants. Stage III plaques
obtained without added tsGll at 38.5 C often
contained as much as 50% of the new ts mutant.
Presumably, such plaques were formed either
by simultaneous infection with two single vi-
ruses or, more likely, by infection with a bipa-
rental aggregate or a heteropolyploid virion. In
such a case, the initial equal MOI for the two
viruses might have caused the yield to be close
to equal.
Stage IV results indicating true cd mutants
will be described below.
Characterization of new temperature-sen-
sitive mutants. The new series of mutants have
been designated as M mutants to denote their
origin in Massachusetts, in accordance with the
recommendations for a uniform VSV ts mutant
nomenclature (4). After the complementation
analysis was completed, the tsM mutants were
assigned numbers in a fashion similar to that of
Pringle (13) where the first numeral denotes the
complementation groups, whereas the last two
numerals indicate the number of the mutant
within the group. Table 2 presents the names of
the mutants, the mutagenesis conditions which
caused them, and their relative efficiency of
plating at 38.5 C to that at 31 C. The diameter
of plaques formed by these mutants was about
equal to that of wild type after 48 h at 31 C
except for tsM601 and tsM502 which required
60 to 72 h to form plaques of comparable size.
Cross-complementation of the M series of
mutants was performed according to Cormack
et al. (4; Table 3). They could be classified into
three distinct complementation groups with
ts5/6-03 'apparently representing a double mu-
tant.
Complementation of the M mutants with
representative group I, II, III, IV, and V mu-
tants from the Glasgow and Orsay collections
was also carried out (Table 4). Mutants tsM301
and tsM302 failed to complement only tsG33
and therefore appeared to be in group III.
Similarly, tsM501 and tsM502 could not supply
TABLE 2. Characteristics of Massachusetts series
temperature-sensitive mutants of VSV
VSV Conditions of Comple- Eof plaque
mutant mutagenesis group formation
tsM301 FUb; 0.75 mg/ml III 4 x 10-4
tsM302 FU; 0.75 mg/ml III 9 x 10-4
tsM303 NA"; 3 min at III 8 x 10-5
pH 4.8
tsM501 FU; 0.75 mg/ml V 5 x 10-5
tsM502 FU; 1.0 mg/ml V 5 x 10-4
tsM601 FU; 0.75 mg/ml VI 2 x 10-4
tsM602 FU; 0.30 mg/ml VI 1 x 10-3
tsM5/6-03 FU; 0.30 mg/ml V, VI 2 x lo-3
Wild type 0.64
a Ratio of plaques formed at 38.5 C to those formed
at 31 C.
b FU, 5-Fluorouracil; NA, nitrous acid.
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TABLE 3. Complementation between M series ts mutants or VSVa
Complementation
ts Mutant
M301 M302 M303 M601 M602 M501 M502 M5/6-03
M301 (3 x 103)b 0.3 0.8 19? 20 30 3 1.8
M302 (4 x 102) 1.1 140 60 50 4.5 2.3
M303 (6 x 102) 12 7.2 8.4 2.2 1.6
M601 (5 x 102) 1.1 13 9.2 0.6
M602 (2 x 103) 27 12 1.2
M501 (5 x 103) 1.2 0.9
M502 (8 x 102) 0.7
M5/6-03 (4 x 104)
a Values in the table are expressed as a complementation index (the ratio of the mixed infection yield to the
yield of the more leaky parent), and are the means from duplicate platings in one to three experiments.
b Values in parentheses are the virus yields obtained in single infections at 39 C in PFU/ml. Wild-type VSV
gave a yield of 5 x 106 PFU/ml under these conditions.
c Italicized values are greater than 1.5 and represent significant complementation between the two mutants.
TABLE 4. Complementation between VSV ts mutants derived from different wild-type strainsa
Complementation
ts
Mutant I H III IV V III III V V VI VI V
Gil G22 G33 G41 045 M301 M302 M501 M502 M601 M602 M5/6-03
Gll (6 x 104)b 8.C 34 6.8 42 210 186 285 11 10 57 130
G22 (5 x 10') 2.3 1.9 10 3.2 2.4 5.2 3.8 3.7 10 20
G33 (1 x 104) 2.1 3.2 0.9 1.0 650 166 15 10 7.0
G41 (3 x 106) 3.1 1.7 2.1 4.8 0.3 0.4 1.7 4.1
045 (3 x 10') 18 10 0.3 0.2 8.9 4.2 1.0
a Values expressed as a complementation index as described in Materials and Methods.
b Values in parentheses are yields obtained from singly infected controls at 39 C.
c Italicized values are greater than 1.5 and represent significant complementation between the two mutants.
the missing function to tsO45 and therefore
appeared to be group V mutants. Mutant
tsM502 did not complement tsG41, but the data
clearly place tsM502 in the same group as
tsM501 (Table 3). Mutant tsG41 complements
poorly and tsM502 grows poorly even at 31 C so
their lack of complementation is understanda-
ble.
It was not possible to associate mutants
tsM601, tsM602, and tsM5/6-03 with known
complementation groups. Mutant tsM602 ap-
pears to belong to a separate complementation
group from those already characterized; we
consider it group VI. The data on tsM601 (Table
4) suggest that it might be in group IV, but its
association with tsM602 (Table 3) and its slow
growth at 31 C make this designation unlikely.
Mutant tsM5/6-03 complements tsG41 quite
well; in spite of its being a double mutant, it is
the best argument that group VI is different
from group IV.
Properties of the ed mutants. Two plaques
derived from stage I of the screen contained 5 to
20% of virus capable of complementing tsGll at
stage III (compared with their titers at 31 C),
but no plaques giving a (+ - +) result at stage
IV. These two mutants have been called cdMl
and cdM2. Table 5 presents their history along
with a comparison of their behavior in stage IV
assays to that of the new ts mutants. When over
1,000 clones derived from complementation
plaques were analyzed, about 1.5% gave a
(+ + +) result. Between 16 and 40% of clones
derived from the ts mutant complementation
plaques gave a (+ - +); none gave the
(+ + +) result, but only 107 were analyzed.
Clones scoring as (+ + +) at stage IV for the
cd mutants might be thought to be wild-type
virus, but recloning of the virus growing without
added helper at 38.5 C gave almost entirely ts
virus with, again, an occasional (+ + +) result.
Even a third serial analysis revealed no stable
wild-type virus. We conclude that 1.5% of the
virus in complementation plaques of the cd
mutants are heteropolyploids or aggregates
which grow at 38.5 C in the absence of helper.
Aside from these rare particles, the plaques
contain tsGll plus 5 to 20% of a cd virus which
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TABLE 5. Comparison of stage IV results for cd and ts mutants
VSV Mutant Conditions of Total No. of 31 C d aNo. scored paositive resultsamutagenesis plaques scoreda plaques showing
complementation5 + - + +++
cdMl NGCd 1.0 mg/ml 628 7 (1.1) 0 7
cdM2 FU"; 0.75 mg/ml 472 8 (1.7) 0 8
tsM303 35 14 (40) 14 0
tsM501 32 5 (16) 5 0
tsM5/6-03 40 16 (40) 16 0
a Plaques arising from plating of complementation plaques (at [*] in Fig. 1) at 31 C.
b Percentage of total is shown in parenthesis.
c Positive results of stage IV assays as described in Fig. 1. The three (+) or (-) symbols represent, left to
right, assays at 31, 38.5, and 38.5 C with added tsGll. All other tested plaques showed a (+ - -) pattern
indicative of a tsGll plaque.
d NG, N-methyl-N'-nitro-N-nitrosoguanidine; and FU, 5-fluorouracil.
does not grow by itself at 31 C or 38.5 C but will
grow in cells which are co-infected by tsGll.
Physical properties of mutant cdMi. To
produce a stock of VSV containing as high as
possible a percentage of cdMl, a plaque origi-
nating from single infection by tsGll and cdMl
was chosen. Such plaques are formed by aggre-
gates or heteropolyploids and arise during stage
IV assays on plates incubated at 38.5 C without
added tsGll. One such plaque was eluted and
mixed vigorously to disaggregate clumps, and
its contents were analyzed by sedimentation
through a sucrose gradient. Portions of the
fractionated gradient were analyzed for VSV at
31 C and 38.5 C. A portion was also assayed for
its ability to complement tsGll in an infective
center assay. Mutant cdMl, detected as com-
plementing virus, cosediments with tsGll, de-
tected at 31 C (Fig. 2). Mutant cdMl therefore
does not contain a large deletion of the VSV
genome.
Virus able to grow at 38.5 C without added
helper was found in two regions of the sucrose
gradient (Fig. 2). Some cosedimented with the
main peak of tsGll; it probably represents
simultaneous infections of cells in the plaque
assay monolayer by tsGll and cdMl in the
peak, because dilutions of the peak fraction
showed nonlinearity of plaque number at 38.5 C
with dilution. Of more interest is the virus
detected at 38.5 C which sedimented ahead of
the main peak. In this region of the sucrose
gradient, approximately equal numbers of
plaques were detected with or without tsGll at
38.5 C, indicating that aggregates or hetero-
polyploids were present (insert to Fig. 2).
DISCUSSION
We have described a new method for selecting
VSV conditional lethal mutants for which the
permissive condition is complementation by
tsGll. In principle, the system could be used
with other ts mutants as the helper in com-
plementation, but none of the mutants we
tested could be used because they were unsatis-
factory in stage I of the screen.
With tsGll, new mutants were isolated after
various mutagenesis procedures. Most of these
were new ts mutants in complementation
groups other than group I. Two mutants showed
no detectable new ts virus and were therefore
designated cd mutants to denote their obligate
complementation dependence.
The new ts mutants were isolated as com-
plementation-dependent mutants and, presum-
ably because of the method of isolation, they all
had very little virus able to grow at 38.5 C, and
they all complemented well. They fell into three
complementation groups when compared
among themselves for complementation. One of
them appeared to be in two complementation
groups and was assumed to be a double mutant.
When the new ts mutants were compared to
the existing Glasgow and Orsay mutants, two of
the complementation groups of the new mu-
tants were congruent with the standard groups.
One of the complementation groups of the new
mutants appeared to complement mutants
from all of the existing groups; this group was
therefore designated group VI, and its mutants
were assigned numbers beginning with a 6. The
New-Jersey serotype of VSV contains six known
complementation groups (14), but up to now
VSV Indiana has had only five. There are only
five well-established VSV Indiana proteins, so
either a sixth protein exists or two of the
complementation groups correspond to one pro-
tein.
The two mutants designated cd are clearly
distinguishable from ts mutants in stage IV of
the screen. Complementation plaques of cd
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FIG. 2. Sedimentation properties of infectious
virus from a cd mutant complementation plaque. A
plaque containing cdMl, which arose on a 38.5 C
plate not seeded with helper in the stage IV assay
(Fig. 1), was eluted in 1.0 ml of medium. This plaque
eluate was layered onto 36 ml of a 5 to 40% sucrose
gradient in phosphate-buffered saline and centrifuged
at 21,000 rpm for 50 min at 4 C in an SW27 rotor.
Sedimentation was from right to left. A hollow rod
attached to tubing was inserted to the bottom of the
gradient, and a Buchler polystaltic pump was used to
collect 1.2-ml fractions which were titered by plaque
assay at 31 C and 38.5 C. In addition, 0.1-ml samples
of each gradient fraction were assayed for the presence
of virus capable of complementing tsGll by an
infective center complementation assay. The insert
shows fractions 11 to 23 with a more sensitive scale.
Symbols: 0, 31 C titer; 0, 38.5 C titer; A, titer of
complementing virus.
mutants never gave rise to virus other than
tsGll which was capable of growth at 31 C but
not at 38.5 C (Table 5). Rare progeny from
complementation plaques are able to grow at
31 C and at 38.5 C in the absence of helper
tsGll. These progeny appear to arise from
mixed particles containing a tsGll genome and
a cd mutant genome; they are not wild-type
virus because they never breed true.
The existence of particles with two genomes
has previously been observed with VSV (20).
They could be aggregates but are more likely
4T, AND BALTIMORE J. VIROL.
true heteropolyploids in which two genomes are
enveloped by a single membrane. Their exist-
ence is demonstrated (Fig. 2) as particles sedi-
menting faster than virions which score with
approximately equal efficiency at 38.5 C with or
without added helper.
The nature of the cd mutants has not been
established. The one which was studied is not a
large deletion mutant because it sediments at
the same rate as standard VSV. In principle, cd
mutants could be missense, nonsense, frame-
shift or deletion mutants. To study them in
detail at this time would be difficult because
the cd stocks contain 80 to 95% of tsGll. Their
study will depend on the isolation of cd mutant
stocks which contain less tsGll or the develop-
ment of a conditional state where they can grow
by themselves. Suppressor cells growing non-
sense mutants would be such a condition.
ACKNOWLEDGMENTS
We thank Nora Meuth for excellent technical help. C. W.
R. was supported by a National Science Foundation Summer
Undergraduate Program; R. D. was supported by a Research
Training Fellowship awarded by the International Agency for
Research on Cancer; D. B. was an American Cancer Society
Research Professor.
This work was supported by grant VC-4E from the
American Cancer Society.
LITERATURE CITED
1. Burge, B. W., and E. R. Pfefferkorn. 1966. Isolation and
characterization of conditional-lethal mutants of sind-
bis virus. Virology 30:204-213.
2. Cairns, J. E., A. F. Holloway, and D. V. Cormack. 1972.
Temperature-sensitive mutants of vesicular stomatitis
virus: in vitro studies of virion-associated polymerase.
J. Virol. 10:1130-1135.
3. Cooper, P. D. 1955. A method for producing plaques in
agar suspensions of animal cells. Virology 1:397-401.
4. Cormack, D. V., A. F. Holloway, and C. R. Pringle. 1973.
Temperature-sensitive mutants of vesicular stomatitis
virus: homology and nomenclature. J. Gen. Virol.
19:295-300.
5. Emerson, S. U., and R. R. Wagner. 1973. L protein
requirement for in vitro RNA synthesis by vesicular
stomatitis virus. J. Virol. 12:1325-1335.
6. Farmilo, A. J., and C. P. Stanners. 1972. Mutant of
vesicular stomatitis virus which allows deoxyribonu-
cleic acid synthesis and division in cells synthesizing
viral ribonucleic acid. J. Virol. 10:605-613.
7. Flamand, A. 1969. Etude des mutants thermosensibles du
virus de la stomatite vesiculaire. Mise au point d'un
test de complementation. C. R. Acad. Sci. Ser. D.
268:2305-2308.
8. Flamand, A. 1970. Etude g6netique du virus de la
stomatite vesiculaire: classement de mutants thermo-
sensibles sponten6s en groupes de complementation. J.
Gen. Virol. 8:187-195.
9. Flamand, A., and C. R. Pringle. 1971. The homologies of
spontaneous and induced temperature-sensitive mu-
tants of vesicular stomatitis virus. J. Gen. Virol.
11:81-85.
10. Granoff, A. 1961. Induction of Newcastle disease virus
mutants with nitrous acid. Virology 13:402-408.
N
SCREENING VSV MUTANTS
11. Holloway, A. F., P. K. Y. Wong, and D. V. Cormack.
1970. Isolation and characterization of temperature-
sensitive mutants of vesicular stomatitis virus. Virol-
ogy 42:917-926.
12. Hunt, D. M., and R. R. Wagner. 1974. Location of the
transcription defect in group I temperature-sensitive
mutants of vesicular stomatitis virus. J. Virol.
13:28-35.
13. Pringle, C. R. 1970. Genetic characterization of condi-
tional lethal mutants of vesicular stomatitis virus
induced by 5-fluorouracil, 5-azacytidine and ethyl
methane sulphonate. J. Virol. 5:559-567.
14. Pringle, C. R., I. B. Duncan, and M. Stevenson. 1971.
Isolation and characterization of temperature-sensitive
mutants of vesicular stomatitis virus, New Jersey
serotype. J. Virol. 8:836-841.
15. Reichmann, M. E., C. R. Pringle, and E. A. C. Follett.
1971. Defective particles in BHK cells infected with
temperature-sensitive mutants of vesicular stomatitis
virus. J. Virol. 8:154-160.
16. Simpson, R. W., and J. F. Obijeski. 1974. Conditional
lethal mutants of vesicular stomatitis virus. 1. Pheno-
typic characterization of single and double mutants
exhibiting host restriction and temperature sensitivity.
Virology 57:357-368.
17. Stampfer, M., D. Baltimore, and A. S. Huang. 1971.
Absence of interference during high-multiplicity infec-
tion by clonally purified vesicular stomatitis virus. J.
Virol. 7:409-411.
18. Szilagyi, J. F., and C. R. Pringle. 1972. Effect of
temperature-sensitive mutations on the virion-
associated RNA transcriptase of vesicular stomatitis
virus. J. Mol. Biol. 71:281-291.
19. Wagner, R. W., A. H. Levy, R. M. Snyder, G. A. Ratcliff,
and D. F. Hyatt. 1963. Biologic properties of two plaque
variants of vesicular stomatitis virus (Indiana sero-
type). J. Immunol. 91:112-122.
20. Wong, P. K. Y., A. F. Holloway, and D. V. Cormack.
1971. A search for recombination between temperature-
sensitive mutants of vesicular stomatitis virus. J. Gen.
Virol. 13:477-479.
21. Zavada, J. 1972. Pseudotypes of vesicular stomatitis virus
with the coat of murine leukaemia and of avian
myeloblastosis viruses. J. Gen. Virol 15:183-191.
VOL. 15, 1975 49
